Reservation chart may soon be prepared 8 hours before train departure
Among the series of measures proposed to ease ticket booking experience and passenger movement, the Indian Railways is mulling to prepare reservation charts eight hours before the departure. This move will reduce uncertainties for passengers with waitlist tickets. The passengers will get the first update on waitlist status well in advance.(Unsplash/Representational Image)
Under this, for trains departing before 14:00 hours, the chart will be prepared the previous day at 21:00 hours.
Currently, the reservation chart is prepared four hours before the departure of the train, which leads to uncertainty for passengers with waitlist tickets.
The passengers will get the first update on waitlist status well in advance. It will benefit passengers travelling from remote locations or suburbs of major cities for catching long distance trains. It will also provide more time to make alternative arrangements in case the wait list is not confirmed.
Meanwhile, Railway minister Ashwini Vaishnaw reviewed the upgradation of the passenger reservation system on Sunday. The project has been executed for the last few months by CRIS.
Under the upgraded PRS, only the authenticated users will be able to book Tatkal tickets on IRCTC website, beginning July 1, 2025.
Further, Tatkal ticket will require OTP-based authentication using Adhaar of any other government verified documents or government id, available at DigiLocker account stated by the railways. Upgraded PRS system
The upgraded PRS (Passenger Reservation System) is designed to be agile, flexible, and scalable, capable of handling ten times the current load. It will significantly boost ticket booking capacity, enabling over 1.5 lakh bookings per minute, an almost fivefold increase from the existing 32,000 tickets per minute.
The new system features a multilingual, user-friendly interface for both booking and enquiries. Users will be able to specify their seat preferences and view a fare calendar. Additionally, the PRS now includes integrated support for Divyangjan, students, patients, and other special user categories
(With ANI inputs)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
35 minutes ago
- New Indian Express
VinFast partners with myTVS for pan-India aftersales service ahead of EV launch
Vietnamese electric vehicle (EV) major VinFast, which is all set to enter the Indian market, has formed a service collaboration with Chennai-based multi-brand aftermarket chain myTVS, a part of the TVS Mobility group. VinFast aims to establish 120 Extended Service Workshops by partnering with potential service providers to boost its aftersales operations across India. Under this strategic collaboration, myTVS will ensure VinFast Customers receive comprehensive service coverage across India. The association focuses on delivering exceptional service quality through workshops equipped with genuine parts, advanced diagnostic and repair equipment, and highly trained technical personnel. 'This strategic collaboration with myTVS to expand our comprehensive after-sales service network demonstrates our long-term commitment to the Indian market and our dedication to customer satisfaction,' said Pham Sanh Chau, CEO, VinFast Asia. The electric carmaker is likely to enter the Indian market by the end of July 2025. As per report, the launch schedule for VinFast's electric SUVs has been postponed by about one month due to insufficient sales network development. Manufacturing operations at Vinfast's Tamil Nadu facility, initially planned to commence on June 30, have been rescheduled to July 30. Last week, VinFast announced plans to showcase its premium electric SUV models, the VF 7 and VF 6, across 11 states and cities in India. Natarajan Srinivasan, CEO, myTVS, said, 'We are confident that this unique partnership will enable VinFast to scale growth backed by our technology powered after-sales service platform. This partnership also validates the myTVS business model of building and delivering a high-quality, convenient, transparent and digitally powered after-market service platform to support the ambitions of India's automobile sector.'
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Foreign banks offer Torrent ₹20,000 cr credit line for JB Chemicals buyout
The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity Mumbai The Torrent group has secured a credit line of up to ₹20,000 crore from a consortium of international lenders, including HSBC, Standard Chartered Bank, and Barclays, to fund its proposed acquisition of JB Chemicals & Pharmaceuticals Ltd, according to a person familiar with the matter. The Ahmedabad-based pharmaceutical firm plans to draw down the facility depending on the subscription to its upcoming open offer, the person said, requesting anonymity. The interest rate on the credit line has been set at a competitive 8 per cent, the person added. Sudhir Menon, chief financial officer at Torrent Pharmaceuticals, told analysts that the
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
KKR's exit from JB Chemicals cements its healthcare track record
KKR & Co's ₹11,900 crore ($1.42 billion) exit from JB Chemicals and Pharmaceuticals marks another successful bet in India's fast-growing healthcare sector, underscoring the US-based private equity giant's strong track record in the space. KKR exited JB Chemicals on Sunday. The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020. The exit follows its blockbuster five-time (5x) return in Max Healthcare in 2022, which remains the largest block deal by a private equity firm in India to date, a person familiar with the matter said. In JB Chemicals, the US-based firm made 36 per cent gross internal rate of return in the exit, including sale of part of its stake via block deal early this year. The JB Chemicals deal adds to KKR's expanding healthcare portfolio in India, which includes stakes in Healthcare Global Enterprises, Baby Memorial Hospital (BMH), Healthium Medtech, and Infinx Healthcare, a US-based healthcare technology firm focused on revenue cycle and patient access solutions. Since the start of 2024, KKR's private equity arm has deployed $2 billion in India. In June, the firm arranged $600 million in financing for the Manipal group through KKR Capital Markets. The deal, anchored by KKR's private credit and insurance platforms, is aimed at supporting Manipal's long-term growth strategy. The Manipal group, which operates Manipal Health Enterprises, one of India's largest multispecialty hospital chains, has been active in the M&A (mergers and acquisitions) market. Manipal had in April 2023 sold a significant stake in its hospital business to Singapore's Temasek Holdings in a transaction valued at nearly $2 billion. KKR's back-to-back healthcare bets come amid rising investor appetite for India's healthcare sector, fuelled by growing demand for quality care, rising incomes, and increased insurance penetration. In 2024, healthcare funding saw an 80 per cent rise in deal volumes, with notable activity in medtech and single-specialty hospitals. The IT/ITeS sector deal value grew 300 per cent, driven by major transactions such as Perficient ($3 billion), Altimetrik ($900 million), and GeBBS ($865 million). Single-specialty hospitals saw particular interest, with deal volumes doubling as investors targeted underpenetrated categories such as eyecare, oncology, and IVF, as per a report by Bain & Company.
